Jerry Sullivan is editor of the Business Journal. He directs the paper's coverage and layout and oversees a team of award-winning reporters. He also oversees the paper's website. He can be reached at firstname.lastname@example.org.
It seemed altogether fitting that three generations of Herberts—all Gavins, by the way—were on hand for the Business Journal’s 15th annual Family-Owned Business Awards last week (see related item, page 8; profiles of winners in next week’s edition).
Are the powers that be rethinking the fate of the two hangars on the former Marine base in Tustin now that Google has signed a 60-year lease worth $1.2 billion for a similar structure and several others on surrounding grounds in the Silicon Valley?
A trot around the South Coast Metro district that covers corners of Costa Mesa and Santa Ana reveals several sizeable chunks of property in a state of flux.
Sometimes the uninitiated are right even when they’re wrong about Orange County.
Not much math but plenty of tea leaves to read on the Pimco-Janus front.
The search is on for a new executive vice chancellor and provost at UCI—a job that’s about on par with a COO’s post in the business world, while the chancellor of the school functions more like a CEO.
Would-be raiders Valeant Pharmaceuticals and Bill Ackman appear to be running out of room for their argument that Allergan CEO David Pyott and his fellow board members overlook shareholders as they fight the hostile bid for the Irvine-based drug maker.
Bill Gross and big numbers go together, as our story on page 1 shows with its estimate on the value of the publicity that came with the Bond King’s jump from Pimco to Janus Capital topping $300 million.
The Insider has no dog in any fight between Bill Gross and whoever—but it now looks clear from this vantage point that a cadre of critics coordinated their condemnations of the cofounder and now ex-boss of Pimco in recent months.
Activist investor Bill Ackman has threatened to sue Allergan Inc. if the Irvine-based drug maker goes ahead with an acquisition of Salix Pharmaceuticals Ltd. in a deal that doesn’t require a vote of Allergan shareholders.